Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibogaine (IV formulation, IBX-210)
- Development stage
- Unknown
- Lead developer
- ATAI Life Sciences
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
IBX-210 is a novel intravenous (IV) formulation of ibogaine, an indole alkaloid derived from the Tabernanthe iboga plant. Ibogaine has been investigated for its potential to treat substance use disorders due to its unique pharmacological profile. The IV formulation aims to improve safety and reduce pharmacokinetic variability compared to oral administration, offering a shorter and more predictable in-clinic experience. IBX-210 is being developed primarily for opioid use disorder (OUD), with clinical trials planned or ongoing in this indication. Mechanistically, ibogaine acts on multiple targets including dopamine transporter (DAT), serotonin transporter (SERT), kappa opioid receptor, NMDA receptor antagonism, and opioid receptor antagonism[2][3][4][8]. The developer is Atai Life Sciences in collaboration with DemeRx[4].
- Other names
- intravenous ibogaineIV-ibogaineibogaine hydrochloride (IV)DMX-1002DMX1002DMX 1002
02
Targets
DAT (Dopamine plasma membrane transport protein)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on ibogaine (IV formulation, IBX-210).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibogaine (IV formulation, IBX-210).